Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0HD8X
|
|||
| Former ID |
DNCL002723
|
|||
| Drug Name |
ISF35
|
|||
| Indication | Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 2 | [1] | |
| Mantle cell lymphoma [ICD-11: 2A85.5; ICD-10: C83.1] | Phase 2 | [1] | ||
| Small lymphocytic lymphoma [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 2 | [1] | ||
| Company |
Memgen
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00942409) Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Non-Hodgkin's Lymphoma (Follicular, Diffuse Large Cell, Mantle Cell, and Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia. U.S. National Institutes of Health. | |||
| REF 2 | Intratumoral injection of Ad-ISF35 (Chimeric CD154) breaks tolerance and induces lymphoma tumor regression. Hum Gene Ther. 2015 Jan;26(1):14-25. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.